The Current Ratio as of November 2024 (TTM) for Eupraxia Pharmaceuticals Inc. (EPRXF) is 1.95

According to Eupraxia Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.95. This represents a change of 28.58% compared to the average of 1.52 of the last 4 quarters.

Eupraxia Pharmaceuticals Inc. (EPRXF) Historical Current Ratio (quarterly & annually)

How has EPRXF Current Ratio performed in the past?

The mean historical Current Ratio of Eupraxia Pharmaceuticals Inc. over the last ten years is 4.05. The current 1.95 Current Ratio has changed 4.72% with respect to the historical average. Over the past ten years (40 quarters), EPRXF's Current Ratio was at its highest in in the June 2021 quarter at 45.15. The Current Ratio was at its lowest in in the September 2019 quarter at 0.

Eupraxia Pharmaceuticals Inc. (EPRXF) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Eupraxia Pharmaceuticals Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Eupraxia Pharmaceuticals Inc. (EPRXF) Average Current Ratio

How has EPRXF Current Ratio performed in the past?

The current Current Ratio of Eupraxia Pharmaceuticals Inc. (EPRXF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Eupraxia Pharmaceuticals Inc. (EPRXF) Current Ratio vs. Peers

How is EPRXF’s Current Ratio compared to its peers?

Eupraxia Pharmaceuticals Inc.’s Current Ratio is less than Adynxx, Inc. (0), greater than Ascletis Pharma Inc. (0), less than AVAX Technologies, Inc. (24.38), greater than Eliem Therapeutics, Inc. (1.61), less than Inhibrx Biosciences, Inc. (60.41), less than Merrimack Pharmaceuticals, Inc. (4.70), less than Celcuity Inc. (10.78), less than Enliven Therapeutics, Inc. (10.36), less than Transgene SA (17.44), greater than Champions Oncology, Inc. (1.57), greater than MAIA Biotechnology, Inc. (0.69), less than Lumos Pharma, Inc. (2.56), less than Processa Pharmaceuticals, Inc. (2.66), less than Alpha Cognition Inc. (3.97), greater than Acurx Pharmaceuticals, Inc. (1.50), greater than Fennec Pharmaceuticals Inc. (1.74), less than null (7.80),

Build a custom stock screener for Eupraxia Pharmaceuticals Inc. (EPRXF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eupraxia Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Eupraxia Pharmaceuticals Inc. (EPRXF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Eupraxia Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.